Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 140,580 shares of the pharmaceutical company's stock after selling 27,036 shares during the quarter. Baillie Gifford & Co. owned about 0.05% of Vertex Pharmaceuticals worth $65,381,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Groesbeck Investment Management Corp NJ increased its holdings in shares of Vertex Pharmaceuticals by 1.2% in the second quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company's stock valued at $841,000 after purchasing an additional 21 shares during the last quarter. Mutual Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company's stock worth $1,751,000 after acquiring an additional 21 shares during the last quarter. Institute for Wealth Management LLC. raised its holdings in shares of Vertex Pharmaceuticals by 0.6% during the 2nd quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company's stock worth $1,681,000 after acquiring an additional 22 shares during the period. Drive Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 2.0% during the 2nd quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company's stock worth $516,000 after acquiring an additional 22 shares during the period. Finally, Daymark Wealth Partners LLC boosted its position in shares of Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company's stock valued at $374,000 after acquiring an additional 22 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company's stock, valued at $2,217,500. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares of the company's stock, valued at $2,217,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.9 %

Shares of Vertex Pharmaceuticals stock traded up $4.61 on Wednesday, reaching $494.61. 963,206 shares of the company were exchanged, compared to its average volume of 1,172,864. The stock's 50 day moving average price is $475.81 and its 200-day moving average price is $470.31. The company has a market cap of $127.38 billion, a P/E ratio of -248.55 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.69 billion. During the same quarter in the previous year, the business posted $3.67 EPS. The firm's revenue was up 11.6% on a year-over-year basis. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and issued a $600.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, October 21st. UBS Group raised their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, Barclays lowered Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $472.00 to $509.00 in a research note on Monday, August 5th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $495.96.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.